Kobayashi Pharmaceutical is reportedly considering going private, and buying interest at the limit-up price continues. The company is said to have received an acquisition proposal through a tender offer from 日本産業推進機構 Group and European investment fund CVC Capital, with a partial investment by the founding family also under consideration. Against the backdrop of the health damage issue, the company is reportedly planning to pursue a turnaround under the ownership of the funds.
Kobayashi Pharmaceutical is reported to have received an acquisition proposal through a tender offer and to be considering going private. The proposers are said to be 日本産業推進機構 Group and European investment fund CVC Capital.
According to the article, the company is said to have received a joint proposal, and there is a view that the shares are moving to reflect an acquisition premium.
The founding family is also reportedly considering making a partial investment, and the company is said to be planning to pursue a turnaround under the ownership of the funds against the backdrop of the health damage issue.